Literature DB >> 28833380

Population pharmacokinetics of the MEK inhibitor selumetinib and its active N-desmethyl metabolite: data from 10 phase I trials.

Parul Patel1, Eleanor Howgate1, Paul Martin2, David J Carlile3, Leon Aarons1, Diansong Zhou4.   

Abstract

AIMS: The aims of the study were to characterize the pharmacokinetics (PK) of selumetinib (AZD6244; ARRY-142886), a mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor in clinical development for various indications, and its N-desmethyl metabolite in healthy volunteers, and evaluate clinically important covariates.
METHODS: A pooled-population PK analysis was performed using a nonlinear mixed-effects approach with plasma concentration data from 346 subjects who received single oral doses of selumetinib 20-75 mg across 10 phase I studies. Absolute bioavailability was determined using intravenous [14 C] selumetinib.
RESULTS: A two-compartment linear model with sequential zero-first order absorption and a lag time for the zero-order process was described for selumetinib PK. N-desmethyl metabolite disposition was described by a single compartment with linear elimination, without back transformation. The parent-only and joint models generally described pooled data adequately. For the median subject, not taking interacting drugs, estimates for clearance (CL) and central volume of distribution (V2) for selumetinib in the final joint model were 12.7 l h-1 and 35.6 l, respectively. Food effects, comedication with itraconazole [a cytochrome P450 (CYP) 3A4 inhibitor], fluconazole (a CYP2C19 inhibitor) and rifampicin (a CYP3A4 inducer) and formulation effects were incorporated into the base model a priori. Race and hepatic function were also influential in the PK model. Additional covariates affecting selumetinib disposition identified from covariate analysis were age on V2, bilirubin on CL, and weight on CL and V2.
CONCLUSIONS: Analysis confirmed previous clinical pharmacology study findings of drug-drug interactions and food effects, with additional covariates that influence selumetinib and N-desmethyl selumetinib PK identified. Dose modifications based on these additional covariates were not considered necessary.
© 2017 The British Pharmacological Society.

Entities:  

Keywords:  metabolites; pharmacokinetics; phase I; selumetinib

Mesh:

Substances:

Year:  2017        PMID: 28833380      PMCID: PMC5736843          DOI: 10.1111/bcp.13404

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

Review 1.  Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications.

Authors:  A A Mangoni; S H D Jackson
Journal:  Br J Clin Pharmacol       Date:  2004-01       Impact factor: 4.335

2.  Population pharmacokinetic modeling of quetiapine after administration of seroquel and seroquel XR formulations to Western and Chinese patients with schizophrenia, schizoaffective disorder, or bipolar disorder.

Authors:  Diansong Zhou; Khanh H Bui; Jianguo Li; Nidal Al-Huniti
Journal:  J Clin Pharmacol       Date:  2015-07-14       Impact factor: 3.126

3.  Joint population pharmacokinetic analysis of zidovudine, lamivudine, and their active intracellular metabolites in HIV patients.

Authors:  C Bazzoli; H Bénech; E Rey; S Retout; D Salmon; X Duval; J M Tréluyer; F Mentré
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

4.  Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor.

Authors:  Tammie C Yeh; Vivienne Marsh; Bryan A Bernat; Josh Ballard; Heidi Colwell; Ron J Evans; Janet Parry; Darin Smith; Barbara J Brandhuber; Stefan Gross; Allison Marlow; Brian Hurley; Joe Lyssikatos; Patrice A Lee; James D Winkler; Kevin Koch; Eli Wallace
Journal:  Clin Cancer Res       Date:  2007-03-01       Impact factor: 12.531

5.  MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model.

Authors:  Chandra Bartholomeusz; Xuemei Xie; Mary Kathryn Pitner; Kimie Kondo; Ali Dadbin; Jangsoon Lee; Hitomi Saso; Paul D Smith; Kevin N Dalby; Naoto T Ueno
Journal:  Mol Cancer Ther       Date:  2015-09-17       Impact factor: 6.261

6.  Metabolism, Excretion, and Pharmacokinetics of Selumetinib, an MEK1/2 inhibitor, in Healthy Adult Male Subjects.

Authors:  Angela W Dymond; Colin Howes; Christine Pattison; Karen So; Gabriella Mariani; Mark Savage; Stuart Mair; Gill Ford; Paul Martin
Journal:  Clin Ther       Date:  2016-10-15       Impact factor: 3.393

7.  Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.

Authors:  Alex A Adjei; Roger B Cohen; Wilbur Franklin; Clive Morris; David Wilson; Julian R Molina; Lorelei J Hanson; Lia Gore; Laura Chow; Stephen Leong; Lara Maloney; Gilad Gordon; Heidi Simmons; Allison Marlow; Kevin Litwiler; Suzy Brown; Gregory Poch; Katie Kane; Jerry Haney; S Gail Eckhardt
Journal:  J Clin Oncol       Date:  2008-04-07       Impact factor: 44.544

8.  A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.

Authors:  Suzanne Leijen; Patricia M M B Soetekouw; T R Jeffry Evans; Marianne Nicolson; Jan H M Schellens; Maria Learoyd; Lynda Grinsted; Victoria Zazulina; Thinn Pwint; Mark Middleton
Journal:  Cancer Chemother Pharmacol       Date:  2011-09-28       Impact factor: 3.333

9.  Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End-Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects.

Authors:  Angela W Dymond; Paul Martin; Karen So; Yifan Huang; Paul Severin; Victoria Holmes; Gabriella Mariani; Thomas Marbury
Journal:  J Clin Pharmacol       Date:  2016-12-26       Impact factor: 3.126

10.  Population Pharmacokinetics of Selumetinib and Its Metabolite N-desmethyl-selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low-Grade Gliomas.

Authors:  Y T Patel; V M Daryani; P Patel; D Zhou; J Fangusaro; D J Carlile; P D Martin; L Aarons; C F Stewart
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-03-22
View more
  6 in total

1.  Population pharmacokinetics and exposure-response of selumetinib and its N-desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas.

Authors:  Stein Schalkwijk; Li Zhou; Sarit Cohen-Rabbie; Lokesh Jain; Tomoko Freshwater; Karen So; Zhongqing He; Ioanna Gioni; Helen Tomkinson; Karthick Vishwanathan; Diansong Zhou
Journal:  Cancer Chemother Pharmacol       Date:  2021-04-26       Impact factor: 3.333

Review 2.  Clinical Pharmacokinetics and Pharmacodynamics of Selumetinib.

Authors:  Olivia Campagne; Kee Kiat Yeo; Jason Fangusaro; Clinton F Stewart
Journal:  Clin Pharmacokinet       Date:  2020-12-23       Impact factor: 6.447

Review 3.  Reviewing the role of healthy volunteer studies in drug development.

Authors:  Joyson J Karakunnel; Nam Bui; Latha Palaniappan; Keith T Schmidt; Kenneth W Mahaffey; Briggs Morrison; William D Figg; Shivaani Kummar
Journal:  J Transl Med       Date:  2018-12-04       Impact factor: 5.531

4.  Population pharmacokinetic model with time-varying clearance for lorlatinib using pooled data from patients with non-small cell lung cancer and healthy participants.

Authors:  Joseph Chen; Brett Houk; Yazdi K Pithavala; Ana Ruiz-Garcia
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-02-01

Review 5.  Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib.

Authors:  Robert Galvin; Adrienne L Watson; David A Largaespada; Nancy Ratner; Sara Osum; Christopher L Moertel
Journal:  Curr Oncol Rep       Date:  2021-03-15       Impact factor: 5.075

6.  Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug-Drug Interactions and Pediatric Dose Regimens.

Authors:  Sarit Cohen-Rabbie; Li Zhou; Karthick Vishwanathan; Martin Wild; Sherrie Xu; Tomoko Freshwater; Lokesh Jain; Stein Schalkwijk; Helen Tomkinson; Diansong Zhou
Journal:  J Clin Pharmacol       Date:  2021-07-22       Impact factor: 2.860

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.